Edwards Lifesciences (EW) Stock Forecast & Price Target

$68.55

+4.01 (+6.21%)

(As of 10/8/2024 ET)

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 27 Analyst Ratings

Sell
0

Hold
15

Buy
12

Based on 27 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 27 analysts, 15 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for EW.

Consensus Price Target

$77.27
12.72% Upside

According to the 27 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $77.27. The highest price target for EW is $105.00, while the lowest price target for EW is $57.00. The average price target represents a forecasted upside of 12.72% from the current price of $68.55.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

EW Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)
Hold	15 Hold rating(s)	13 Hold rating(s)	5 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$77.27	$82.10	$95.24	$91.50
Forecasted Upside	12.72% Upside	22.89% Upside	1.55% Upside	25.53% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Hold

[SHOCKING] Crypto Document Leak… (Ad)

The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.

Download your digital copy now

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	S&P 500
Consensus Rating Score	2.48	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	13.07% Upside	10,819.51% Upside	7.88% Upside
News Sentiment Rating	Neutral News See Recent EW News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/8/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$85.00 ➝ $75.00	+9.41%
10/7/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Hold ➝ Hold	$77.00 ➝ $66.00	+2.10%
10/1/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$83.00 ➝ $77.00	+17.36%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$76.00 ➝ $70.00	+6.69%
9/18/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$85.00 ➝ $70.00	+4.14%
9/13/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$82.00 ➝ $71.00	+1.23%
Get the Latest News and Ratings for EW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.
9/12/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $90.00	+34.71%
9/10/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$90.00 ➝ $75.00	+12.66%
9/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $80.00	+21.34%
9/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $80.00	+19.47%
7/31/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
7/29/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
7/26/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$107.00 ➝ $91.00	+44.72%
7/25/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Jennings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $70.00	+14.27%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$103.00 ➝ $85.00	+34.60%
7/25/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$85.00 ➝ $70.00	+3.61%
7/25/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$88.00 ➝ $73.00	-16.04%
7/25/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$105.00 ➝ $75.00	-13.74%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$102.00 ➝ $70.00	-19.49%
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$105.00 ➝ $72.00	-17.19%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $105.00	+14.78%
3/26/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Mixed ➝ Positive
3/21/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$95.00 ➝ $103.00	+8.72%
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$75.00	+4.90%
6/27/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
2/6/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Underperform	$95.00 ➝ $66.00	-13.23%
10/28/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $100.00	+38.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:12 PM ET.

EW Forecast - Frequently Asked Questions

: According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $77.27, with a high forecast of $105.00 and a low forecast of $57.00.
: 27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 15 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
: According to analysts, Edwards Lifesciences's stock has a predicted upside of 12.72% based on their 12-month stock forecasts.
: Over the previous 90 days, Edwards Lifesciences's stock had 7 downgrades and 3 upgrades by analysts.
: Edwards Lifesciences has been rated by research analysts at Baird R W, Bank of America, Barclays, Canaccord Genuity Group, Citigroup, Daiwa America, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group, JPMorgan Chase & Co., Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating for Edwards Lifesciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EW compares to other companies.